Conditions: BRAF or NRAS Mutant Metastatic Melanoma
Keywords: Metastatic melanoma, BRAF-mutant, NRAS-mutant
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 183
Healthy volunteers: no

Brief summary:
The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.

Detailed description:

Arms:
arm 1: BRAFV600 mutant, 45mg bid MEK162 arm 2: NRAS mutant, 45mg bid MEK162 arm 3: BRAFV600 mutant, 60mg bid MEK162

Interventions: intervention 1: MEK162
Intervention descriptions: intervention 1: None

Protocol document: